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Transcriptional regulation by RNA polymerase II 
(RNA Pol II) is a highly regulated process involving the 
action of multiple transcription factors that collectively 
regulate synthesis of messenger RNA (mRNA). These 
complexes sit atop core promoter regions of DNA 
composed of sequence motifs that mark the starting 
point of transcription [1]. Studies have shown that the 
transcriptional machinery is capable of sensing changes in 
cellular stress levels and directing cell fate by modulating 
production of genes involved in cell cycle regulation 
[2]. Very few molecules are capable of directly targeting 
transcription, making this an area of intense therapeutic 
interest. In this issue of Oncotarget, Morachis et al. 
describe identification of three distinct drugs that inhibit 
mRNA synthesis [3]. Surprisingly, these drugs, Hypericin, 
Rottlerin, and SP600125 (Figure 1), are kinase inhibitors 
that impair transcription initiation by targeting components 
of the Pol II pre-initiation complex. A common target of 
these compounds is the inhibition of the TATA binding 
protein which helps position Pol II along the transcription 
start site of p53-responsive promoters. Development of 
this  new  methodology,  together  with  identification  of 
these compounds as transcriptional inhibitors, will pave 
the way toward providing mechanistic insight into cause 
and treatment of disease. 
The p53 tumor suppressor protein promotes 
longevity by reducing somatic mutations or the survival 
and proliferation of mutant cells [4]. Almost all human 
cancers contain impairments in the p53 signaling pathway. 
Currently, intense focus centers on understanding how 
p53 chooses which of its multiple target genes to activate 
or repress in response to a given stress. A potential source 
enabling the diverse functions of p53 lies within the core 
promoter regions of its target genes [5]. The core promoter, 
where transcription is initiated, contains conserved motifs 
such as TATA box, initiator (INR), TFIIB recognition 
element (BRE), down-stream promoter element (DPE) 
and down-stream core element (DCE) (Figure 2) [6]. 
Morachis et al. analyzed the impact of multiple kinase 
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Figure 1: Structural representations of the kinase inhibitors Hyericin, Rottlerin, and SP600125. Hyerpericin is an antibiotic 
and one of the principle ingrediants in Saint John’s wort. Rottlerin is extracted from the Kamala plant Mallotus philippinensis, and is a widely-
used selective inhibitor of protein kinase C. SP600125 is inhibitor of c-Jun N-terminal kinase (JNK).Oncotarget 2011; 2:  5 - 7 6 www.impactjournals.com/oncotarget
inhibitors on RNA transcriptional activity along three p53 
target gene core regulatory elements using transcription 
and electrophoretic mobility shift (EMSA) assays. And, 
while other drugs such as Flavopiridol were shown to 
abolish transcription during the elongation phase [7], this 
study reports that Hypericin, Rottlerin, and SP600125 
inhibit modification of the TATA Binding Protein (TBP) 
during the initial phase of transcription. Importantly, the 
study further determines that the three compounds inhibit 
TBP phosphorylation on both TATA box-containing and 
TATA-less promoters. A previous study demonstrated that 
yeast TBP could be phosphorylated by the protein kinase 
CK2, thus reducing its affinity to the TATA element [8], 
thus offering a potential mechanism of action. In summary, 
these  findings  add  to  the  limited  toolbox  available  to 
scientists studying transcriptional regulation and may 
aid in development of new therapeutic candidates to treat 
disease. 
The same group has recently demonstrated that 
p53 target promoters are structurally diverse and 
display pronounced differences in Poll II occupancy [9]. 
Their studies reveal that, far from being a latent tumor 
suppressor, p53 functions in a temporal manner to regulate 
promoter activity both before and after cellular stress. This 
is achieved by the ability of p53 to establish markedly 
different affinities of Poll II on its diverse target promoters 
and recruit transcriptional initiation components in a 
stress-specific manner. It will be important to determine 
how p53 directs the recruitment of Poll II and specific 
cofactors to its diverse target promoters before and after 
stress to generate the appropriate transcriptional response 
and how this process fails in human cancers.
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Figure 2: The multi-subunit general transcription apparatus. PIC assembly begins with subunits recognizing the core promoter 
elements, followed by coordinated accretion of the complex machinery. TBP binding to the TATA box is an intrinsically slow step, yielding 
a long-lived protein–DNA complex. TBP phosphorylation is necessary to enable the complex to move from the initiation (top image) to 
the elongation phase of transcription (bottom image).  Kinase inhibiting compounds such as Hypericin, Rottlerin, and SP600125, prevent 
phosphorylation of TBP thus preventing the Poll II complex from progressing to the elongation phase. Oncotarget 2011; 2:  5 - 7 7 www.impactjournals.com/oncotarget
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